行情

IBIO

IBIO

IBIO
AMEX

实时行情|Nasdaq Last Sale

1.950
-0.030
-1.52%
已收盘, 19:58 10/20 EDT
开盘
2.020
昨收
1.980
最高
2.020
最低
1.920
成交量
659.98万
成交额
--
52周最高
7.45
52周最低
0.0500
市值
3.52亿
市盈率(TTM)
-1.9771
分时
5日
1月
3月
1年
5年
新闻
财报
公告
公司事件
分析
简况
iBio Announces Appointment of Dr. Linda Armstrong to Board of Directors
finviz · 6天前
iBio Announces Financial Results for Fiscal Year Ended June 30, 2020
finviz · 10/13 20:05
隔夜美股 | 三大指数下跌,新股生物制药公司C4 Therapeutics(CCCC.US)收涨34.16%
智通财经网 · 10/02 23:00
美股异动 | 抗疫概念股逆市走高,Co-Diagnostics(CODX.US)涨超8%
智通财经网 · 10/02 14:09
美股盘前必读:特朗普确诊新冠 全球市场集体走低
同花顺财经 · 10/02 12:34
美股前瞻 | 三大股指期货大幅下挫,特斯拉(TSLA.US)盘前跌逾4%
金融界 · 10/02 11:15
盘前异动 | 美股阴霾笼罩,抗疫概念股逆市大涨
富途资讯 · 10/02 08:34
隔夜美股 | 三大指数下跌,阳光动力(SPI.US)收涨超1230%
智通财经网 · 09/23 22:00
更多
财务预测
每股收益每股净资产每股现金流
实际值(美元)
预测值(美元)
利润表更多
净利润营业总收入营业利润
净利润(美元)
同比(%)
资产负债表更多
总资产(美元)
总负债(美元)
资产负债率(%)
现金流表更多
经营现金流投资现金流筹资现金流
经营现金流(美元)
同比(%)
了解IBIO最新的财务预测,通过IBIO每股收益,每股净资产,每股现金流等数据分析IBIO近期的经营情况,然后做出明智的投资选择。
EPS
机构持股
总机构数: 16
机构持股: 33.22万
持股比例: 0.18%
总股本: 1.80亿
类型机构数股数
增持
4
1.41万
建仓
2
1.98万
减持
3
6,983
平仓
1
250
  • 业绩
  • 资产分布
  • 分红历史
暂无数据
所属板块
制药
+0.01%
制药与医学研究
-0.26%
高管信息
Chairman/Chief Executive Officer/Director
Thomas Isett
President
Robert Erwin
Chief Accounting Officer
John Delta
Director
Linda Armstrong
Director
Robert Kay
Director
Alexandra Kropotova
Director
Gary Sender
Independent Director
Glenn Chang
Independent Director
Seymour Flug
Independent Director
James Hill
Independent Director
John McKey
Independent Director
Philip Russell
  • 分红
  • 拆股
  • 内部人交易
暂无数据
注册即可获得3个月
免费美股Level2深度行情
(Nasdaq Totalview)
立即领取
IBIO 简况
iBio, Inc. is a biotechnology company. The Company is focused on commercializing its technologies and product candidates and providing product development and manufacturing services to clients and collaborators. Its technologies include iBioLaunch technology and iBioModulator. The Company's technologies constitute a transformative platform for development and production of biologics in hydroponically grown green plants. The Company is focused on the commercialization of its plant-based protein expression technologies for vaccines and therapeutic proteins and on developing and commercializing select biopharmaceutical product candidates. The Company's technology is applicable in a range of product candidates, including products against fibrotic diseases, vaccines, enzyme replacements, monoclonal antibodies, and recombinant versions of marketed products that are derived from human blood plasma.
展开
热门股票
代码
价格
涨跌幅

微牛提供Ibio Inc(AMEX-IBIO)的股票价格、实时市场报价、专业分析师评级、深度图表和免费的IBIO股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易IBIO股票基本功能。